Bird & Bird advises Exciva on Series B financing of €51 Mio.
Contacts
International law firm Bird & Bird has advised German biopharmaceutical company Exciva GmbH on a €51 million Series B financing round. Investors Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.
Exciva was founded in 2016 to address neuropsychiatric symptoms in Alzheimer’s disease dementia and other brain disorders. Based in Heidelberg, Exciva uses its powerful discovery potential, which has led to the combination of two CNS-active compounds to treat agitation in patients living with Alzheimer’s disease dementia.
The proceeds will primarily fund a phase 2 study evaluating the therapeutic potential of Deraphan (a test subject for treating agitation in patients with Alzheimer’s disease).
Exciva has been advised by the following Bird & Bird lawyers: Counsel Andrea Schlote (lead), partner Stefan Münch, Associate Philipp Moosbauer and Project Lawyer Cedric Rao (all Corporate, Munich), partner Dr. Stephan Waldheim (Commercial, Düsseldorf), partner Alexandre Vuchot (Commercial, Paris), partner Dr. Rolf Schmich (Tax, Frankfurt).